Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003907 · ClinicalTrials.gov registry record · Phase 2
Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00003907 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 50 participants.
The verdict
NCT00003907, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor. PURPOSE: Phase II trial to study the effectiveness of chemoembolization in treating patients who have primary liver cancer or metastases to the liver that cannot be surgically removed.
Interventions
- DRUG cisplatin
- DRUG doxorubicin
- DRUG mitomycin
- PROCEDURE embolization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 1999-12-15 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003907
The ClinicalTrials.gov registry entry for NCT00003907 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cisplatin is the first listed.
NCT00003907 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003907 about?
NCT00003907 is a clinical study titled "Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver". RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor. PURPOSE: Phase II trial to study the effectiveness of chemoembolization in treating patients who have primary liver cancer or metastases to the liver that cannot be ...
What is the current status of trial NCT00003907?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 1999-12-15. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00003907?
The interventions under investigation include: cisplatin (DRUG), doxorubicin (DRUG), mitomycin (DRUG), embolization (PROCEDURE).
Who is sponsoring clinical trial NCT00003907?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.